Quarterly Activities and Cashflow Report Jul 31, 2023 06:00AM
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth Jul 3, 2023 06:00AM
Quarterly Activities and Cashflow Report Apr 28, 2023 06:00AM
Quarterly Activities and Cashflow Report Jan 30, 2023 06:23PM
Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference Oct 4, 2022 06:00AM


Jul 29, 2022 06:00AM Quarterly Activities Report for June 2022
Jun 13, 2022 04:30PM Bionomics Investor Webinar
Jan 14, 2022 07:06AM Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to Ring the Nasdaq Stock Market Closing Bell on Friday January 14, 2022
Jan 12, 2022 06:00AM Bionomics Limited participated in the H.C Wainwright BioConnect Conference
Dec 16, 2021 06:00AM Bionomics Limited Announces Pricing of Initial Public Offering in the United States
Dec 1, 2021 06:00AM U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders
Nov 23, 2021 06:37AM Bionomics Files Registration Statement for Proposed Initial Public Offering in the United States
Nov 1, 2021 06:00AM Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study
Sep 20, 2021 06:00AM Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial